06.29.17
TiGenix NV, a biopharma company focused on developing therapies leveraging anti-inflammatory properties of allogeneic, or donor-derived, stem cells, has opened a U.S. office in Cambridge, MA. Establishing U.S. operations will support its strategic goal of developing and commercializing its lead product, Cx601, for the treatment of complex perianal fistulas in Crohn's disease patients, in the U.S.
The U.S. operations are based at the Cambridge Innovation Center in Kendall Square, at the epicenter of the Boston-area biotech hub. TiGenix is in the process of appointing a senior team to support the U.S. and Canadian launch of its global Phase III trial for Cx601.
TiGenix anticipates initiating patient recruitment for the trial in North American centers in 1H18. The global trial is designed to support a future U.S. Biologics License Application (BLA) to the FDA.
Eduardo Bravo, chief executive officer of TiGenix said, "It is very exciting to be establishing TiGenix at the heart of one of the world's leading biotechnology hubs. We are working hard to progress the development of Cx601 in the U.S. and having a team based in Cambridge will add further momentum to these efforts to bring a new treatment option to U.S patients suffering from this severe and debilitating complication of Crohn's disease."
The U.S. operations are based at the Cambridge Innovation Center in Kendall Square, at the epicenter of the Boston-area biotech hub. TiGenix is in the process of appointing a senior team to support the U.S. and Canadian launch of its global Phase III trial for Cx601.
TiGenix anticipates initiating patient recruitment for the trial in North American centers in 1H18. The global trial is designed to support a future U.S. Biologics License Application (BLA) to the FDA.
Eduardo Bravo, chief executive officer of TiGenix said, "It is very exciting to be establishing TiGenix at the heart of one of the world's leading biotechnology hubs. We are working hard to progress the development of Cx601 in the U.S. and having a team based in Cambridge will add further momentum to these efforts to bring a new treatment option to U.S patients suffering from this severe and debilitating complication of Crohn's disease."